Kanamycin-Pos

Kanamycin Monosulphate, the active ingredient in Kanamycin-Pos, is an aminoglycoside antibiotic presented as an ophthalmic preparation for ocular use. It treats bacterial conjunctivitis, keratitis and other ocular bacterial infections in patients requiring topical therapy. The product complies with European Union quality standards and is formulated for single‑dose administration.

GNH USA supplies Kanamycin-Pos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable cold‑chain logistics where required and adhering to stringent import regulations.

Kanamycin-Pos is an aminoglycoside antibiotic used to treat bacterial infections of the eye. - Bacterial conjunctivitis: reduces bacterial load and accelerates resolution of redness and discharge. - Keratitis: eradicates causative organisms, promoting corneal healing and preventing scarring. - Other ocular bacterial infections: provides broad‑spectrum coverage to control infection and preserve visual function.

Topical kanamycin may cause local and systemic adverse reactions, most of which are mild and reversible. Common Side Effects: - Eye irritation: transient burning or stinging after drop application. - Redness: mild conjunctival hyperemia. - Tearing: increased lacrimation. Serious or Rare Side Effects: - Corneal ulceration: deterioration of corneal epithelium. - Allergic reaction: swelling, rash, or eosinophilic inflammation. - Systemic ototoxicity: rare hearing loss with significant absorption.

When using Kanamycin‑Pos, clinicians should observe several safety measures to minimise adverse outcomes. - Assess renal function: evaluate patient’s kidney status before initiating therapy. - Monitor for hypersensitivity: discontinue if signs of allergic reaction appear. - Avoid prolonged use: limit duration to the prescribed period to reduce resistance risk. - Use with caution in neonates and infants: ocular surface is more permeable. - Do not combine with other aminoglycoside eye drops: increased toxicity risk. - Store at below 25°C: keep in original container, protect from moisture and light.

Kanamycin‑Pos can interact with other medicines, affecting safety or efficacy. Major Interactions (Avoid): - Concurrent use with other aminoglycoside ophthalmic preparations: additive ototoxic and nephrotoxic risk. - Co‑administration with loop diuretics (e.g., furosemide): heightened nephrotoxicity. - Systemic use of nephrotoxic agents (e.g., vancomycin): increased renal impairment potential. Moderate Interactions (Monitor Closely): - Topical corticosteroids: may mask infection signs. - Non‑steroidal anti‑inflammatory eye drops: possible additive irritation. - Systemic aminoglycosides: monitor serum levels if both routes are used.